Thank you for your reply and correcting my typo. I noticed it after posting it. But by then I cannot modify it. For some reason, I am only allowed one post a day because I posted all the Merck vaccine manufacturing facilities. I did it one and half years ago and no one paid attention. Then this year someone took it seriously.
I share your feeling: I am also truly blessed and happy to jump on board.
Since I am only allowed one post a day, I am going to put something extra here.
Everyone is talking about why $NWBO acquired Advent. My question is: why could Merck not acquire Advent? Many longs on this board are really doubtful about the connections between those trials conducted at Mayo and Moffitt Cancer Center and $NWBO. But they should not doubt about the connections between those trials and Merck. I have listed all the payments by Merck to all those member of the Mayo research team that has been working on DC vaccine trials.
Mayo can pulse autologous DCs with allogeneic tumor lysate to treat the most difficult cancer and delivered amazing results. Advent can process allogeneic cell therapy. Merck can easily acquired two spin-offs: Mill Creek Life Sciences from Mayo Clinic and Immunorestoration from UPenn, and they combine both with Advent and more than its 20 novel mechanisms to build an empire of DC vaccine therapy immediately. By doing so, Merck can also easily push $NWBO to bankruptcy and then collect all our IPs later.
Obviously, Merck cannot do things this way. The reason is simple. All these DC trials that have amazing efficacy have to use the core technology from $NWBO. Seriously, how could Merck be so silly to run trials which include Pfizer's Prenvar 13 while Merck has its own kind?
Market Data 
Markets 
AI
